Risk Factors for Failure in Glaucoma Patients Undergoing Microshunt Implantation.
Alessandro Rabiolo, Rebecca Toscani, Matteo Sacchi, Pietro Destefanis, Paolo Bettin, Carlo Ciampi, Antonella Clemente, Carlo Alberto Cutolo, Karl Mercieca, Michele Iester, Carlo Enrico Traverso, Maita Marco Di, Calzi Gaia Li, Paolo Nucci, Francesco Bandello, Giacinto Triolo, Cillà Stefano De
Summary
This study identified risk factors for Microshunt failure, highlighting the importance of high intraoperative MMC dose and careful patient selection to optimize surgical success.
Abstract
PURPOSE
To evaluate risk factors for failure of Microshunt in glaucoma patients.
DESIGN
Multicenter retrospective cohort study.
METHODS
The study included 220 eyes from 220 consecutive glaucoma patients undergoing Microshunt implantation at six glaucoma units. Four intraocular pressure (IOP) success criteria were defined: (A) IOP ≤21 mm Hg with ≥20% IOP reduction; (B) IOP ≤18 mm Hg with ≥20% IOP reduction; (C) IOP ≤15 mm Hg with ≥25% IOP reduction; and (D) IOP ≤12 mm Hg with ≥30% IOP reduction from baseline. Kaplan-Meier analysis was used to estimate success rates according to the criteria above, and multivariable Cox models were used to identified risk factors for failure according to criterion A.
RESULTS
Success rates varied based on different criteria, ranging from 43.3% to 62.5% (overall success for criteria D and A, respectively) and from 35.3% to 44.4% (complete success for criteria D and A, respectively) at 1-year follow-up. Higher intraoperative MMC concentration was associated with reduced risk of failure to maintain complete (0.4 vs 0.2 mg/mL: hazard ratio [HR] = 0.441, P < .001) and overall (0.4 vs 0.2 mg/mL: HR = 0.360, P = .004) success. For complete success, other risk factors for failure were pseudoexfoliation glaucoma/pigmentary glaucoma (HR = 1.641, P = .004), primary angle closure glaucoma (HR = 1.611, P < .001), and previous non-glaucomatous ocular surgeries (HR = 2.301, P = .002). For overall success, other risk factors for failure were lower preoperative IOP (for 1-mm Hg increase, HR = 0.934, P = .005), higher number of preoperative antiglaucoma agents (HR = 1.626, P < .001), and Microshunt combined with cataract surgery (HR = 1.526, P = .033).
CONCLUSIONS
This study identified risk factors for Microshunt failure, highlighting the importance of high intraoperative MMC dose and careful patient selection to optimize surgical success.
More by Alessandro Rabiolo
View full profile →Risk Factors for Fast Visual Field Progression in Glaucoma.
Longitudinal Macular Structure-Function Relationships in Glaucoma.
Comparison of Methods to Detect and Measure Glaucomatous Visual Field Progression.
Top Research in IOP & Medical Therapy
Browse all →The Complications of Myopia: A Review and Meta-Analysis.
Inflammation in Glaucoma: From the back to the front of the eye, and beyond.
Treatment Outcomes in the Primary Tube Versus Trabeculectomy Study after 1 Year of Follow-up.
Discussion
Comments and discussion will appear here in a future update.